December 16, 2020
How collaboration will strengthen the future of cell and gene therapies
Recently, COVID-19 shined a light on the existing frailties and resilience of the cell and gene therapy (CGT) ecosystem. Shifting priorities, delayed clinical trials, lab closures and heightened risks for immunocompromised patients threatened the research, development, manufacturing and delivery of CGTs. As clinical science continues to deliver on the promise of CGT, how can the industry make them available and affordable at scale? An EY article provides details.